Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-xylosyl-10-deacetylbaccatin III is a natural taxane derivative isolated from the needles and bark of yew trees, particularly the Chinese yew (*Taxus chinensis*). Developed by Hainan Yew Pharm (Hainan Hongshanshu Pharmaceutical), this small molecule is a structural analogue of paclitaxel and serves as both a potential antineoplastic agent and a key intermediate for the semi-synthesis of other taxoids. Its mechanism of action is consistent with the taxane class, involving the stabilization of microtubules. By binding to tubulin, it promotes the assembly of microtubules and inhibits their disassembly, which disrupts the dynamic instability necessary for mitotic spindle formation. This interference leads to cell cycle arrest at the G2/M phase and ultimately triggers apoptosis in rapidly dividing cancer cells. Hainan Yew Pharm has included this compound in its oncology pipeline for the potential treatment of various solid tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-xylosyl-10-deacetylbaccatin III.